Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time inference of the end of an outbreak: Temporally aggregated disease incidence data and under-reporting.

Infectious Disease Modelling·2025
Same author

The burden of ascites in cirrhosis.

Acta clinica Belgica·2025
Same author

Unravelling the coagulation paradox in liver cirrhosis: challenges and insights.

Acta clinica Belgica·2025
Same author

Fatal acute pulmonary embolism following endoscopic cyanoacrylate injection for gastric fundal varices.

Acta gastro-enterologica Belgica·2025
Same author

Recurrent rejections after liver transplantation for hepatocellular carcinoma with stem cell features in an adult patient.

Acta clinica Belgica·2024
Same author

A remarkable presentation of a massive Budd-Chiari syndrome.

Acta gastro-enterologica Belgica·2023

Related Experiment Video

Updated: Jun 4, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Radionuclide therapy for hepatocellular carcinoma.

B Lambert1, H Van Vlierberghe, R Troisi

  • 1Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium. Bieke.Lambert@Ugent.be

Acta Gastro-Enterologica Belgica
|February 9, 2011
PubMed
Summary

Yttrium-90 (90Y) microspheres show promise for hepatocellular carcinoma (HCC) treatment. Ongoing trials will clarify its role in palliative care and downstaging for surgical candidates.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Area of Science:

  • Hepatobiliary oncology
  • Radiopharmacology
  • Interventional radiology

Background:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • Various radionuclide therapy techniques are emerging for HCC management.
  • Yttrium-90 (90Y) microspheres represent a key modality in this field.

Purpose of the Study:

  • To provide an overview of available radionuclide treatment modalities for HCC.
  • To emphasize the role and application of Yttrium-90 (90Y) microspheres.
  • To review clinical data on safety and outcomes.

Main Methods:

  • Literature screening for clinical data on radionuclide therapies in HCC patients.
  • Focus on Yttrium-90 (90Y) microspheres, including commercial products and practical aspects.
  • Summarization of relevant studies concerning patient selection, safety, and outcomes.

Main Results:

  • Large retrospective and cohort studies demonstrate the safety of 90Y-microspheres in palliative HCC treatment for Child-Pugh A or B7 cirrhosis patients.
  • Selective Internal Radiation Therapy (SIRT) using 90Y-microspheres has been reported for downstaging patients to curative surgery.
  • Randomized trials are underway to compare 90Y-microspheres with other treatments like biotherapy and chemoembolization.

Conclusions:

  • 90Y-microspheres are a safe option for palliative HCC treatment in specific patient groups.
  • Further research is needed to establish the efficacy of 90Y-microspheres against chemoembolization and sorafenib.
  • The role of 90Y-microspheres in downstaging HCC for surgical resection requires continued investigation.